Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after taxus liberte Paclitaxel-eluting coronary stent placement
BACKGROUND: The TAXUS Liberte Post Approval Study (TL-PAS) contributed patients treated with TAXUS Liberte paclitaxel-eluting stent and prasugrel to the Dual Antiplatelet Therapy Study (DAPT) that compared 12 and 30 months thienopyridine plus aspirin therapy after drug-eluting stents. METHODS AND RESULTS: Outcomes for 2191 TL-PAS patients enrolled into DAPT were assessed. The DAPT coprimary composite end point (death, myocardial infarction [MI], or stroke) was lower with 30 compared with 12 months prasugrel treatment (3.7% versus 8.8%; hazard ratio [HR], 0.407; P30 months. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00997503.
School of Medicine